OxyDolor 40mg is an oral prolonged-release solid pharmaceutical preparation containing oxycodone hydrochloride<\/b> (manufactured and distributed across European jurisdictions by G.L. Pharma GmbH and distributed internationally as a bioequivalent generic alternative to reference products such as OxyContin and Longtec). Chemically designated as $(5R,9R,13S,14S)\\text{-4,5}\\alpha\\text{-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride}$<\/span>, oxycodone is a semi-synthetic thebaine-derived phenanthrene opioid alkaloid. Structurally, it consists of a fused pentacyclic morphinan skeleton with a carbon-4 to carbon-5 furan bridge, a methoxy moiety at carbon-3, a tertiary hydroxyl group at carbon-14 (which enhances stereospecific binding at the $\\mu$<\/span>-opioid receptor while attenuating non-immunological peripheral histamine degranulation), and an aliphatic ketone functional group at carbon-6. Its empirical formula as a hydrochloride salt is $\\text{C}_{18}\\text{H}_{21}\\text{NO}_4\\cdot\\text{HCl}$<\/span>, yielding an average molecular weight of $351.82\\text{ g\/mol}$<\/span> (unconjugated active base: $315.36\\text{ g\/mol}$<\/span>).<\/p>\n Standard solid oral presentations of OxyDolor 40mg in the United Kingdom and European Union appear as round, biconvex, orange-colored film-coated prolonged-release tablets (often marked with manufacturer debossments such as “OX 40” or “G.L.”). The prolonged-release mechanism utilizes an insoluble or hydrophilic polymer-based diffusion-matrix system (typically employing ammonio methacrylate copolymers, hypromellose, or ethylcellulose) blended with non-active pharmaceutical excipients including lactose monohydrate, povidone (K30), talc, magnesium stearate, macrogol, and colorants such as iron oxide yellow\/red (E172) and titanium dioxide (E171). This polymer network meters drug diffusion across the gastrointestinal tract over a 12-hour period<\/b>, attenuating sharp plasma peaks and sustaining therapeutic systemic levels.<\/p>\n Within the United Kingdom and European regulatory frameworks:<\/p>\n Medicinal Classification:<\/b> Categorized as a Prescription Only Medicine (POM)<\/b> under the Human Medicines Regulations 2012.<\/p>\n<\/li>\n Controlled Drug Scheduling (UK):<\/b> Under the Misuse of Drugs Act 1971, oxycodone is scheduled as a Class A controlled substance<\/b>. Under the Misuse of Drugs Regulations 2001, OxyDolor 40mg sits within Schedule 2 (CD POM)<\/b>. Prescriptions are subject to strict statutory requirements:<\/p>\n Maximum legal prescription validity of 28 days<\/b> from the date of signature.<\/p>\n<\/li>\n Mandatory declaration of exact formulation, strength, dosing instructions, and total quantity written in both words and figures<\/b>.<\/p>\n<\/li>\n Subject to Safe Custody requirements<\/b> (must be secured in a locked Controlled Drugs cupboard conforming to BS 2881 standards within pharmacies and clinical facilities) and mandatory registration within the statutory Controlled Drugs Register.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n European Status (e.g., Austria, Germany):<\/b> Regulated as a high-tier narcotic analgesic under local controlled substance acts (e.g., Suchtgift<\/i> in Austria; Bet\u00e4ubungsmittel (BtM)<\/i> in Germany, requiring specialized serialization and reporting).<\/p>\n<\/li>\n NHS Formulary Positioning:<\/b> Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff for Step 3 opioid management.<\/p>\n<\/li>\n<\/ul>\n An individual 40mg unit represents a substantial opioid payload, delivering the clinical equivalent of approximately $60\\text{ to }80\\text{ mg}$<\/span> of oral morphine sulphate<\/b>. Consequently, OxyDolor 40mg is heavily targeted on illicit secondary markets (often traded alongside other diverted 40mg preparations as “Oxy 40s” or “Oranges”). Bypassing the prolonged-release matrix via mechanical crushing, chewing, or extraction (dose-dumping<\/b>) causes rapid systemic absorption capable of inducing fatal respiratory depression, particularly in opioid-naive or non-tolerant individuals. Furthermore, counterfeit tablets mimicking European OxyDolor blisters increasingly circulate on illicit markets, containing unpredictable quantities of illicit fentanyl or high-potency synthetic nitazene analogues<\/b> (e.g., metonitazene, protonitazene).<\/p>\n The pharmacodynamic profile of oxycodone is characterized by potent, high-affinity agonism at central and peripheral opioid receptors, primarily within the ascending nociceptive and descending inhibitory pathways:<\/p>\n $\\mu$<\/span>-Opioid (MOP) Receptor Agonism:<\/b> Oxycodone acts as a full agonist at human $\\mu$<\/span>-opioid receptors distributed across the laminae I and II of the spinal dorsal horn, periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and cortical pain processing regions:<\/p>\n Receptor binding activates coupled heterotrimeric inhibitory $G_{\\alpha i\/o}$<\/span> proteins, inhibiting adenylyl cyclase and lowering intracellular cyclic adenosine monophosphate (cAMP).<\/p>\n<\/li>\n Presynaptically, activation closes voltage-gated N-type calcium ($Ca^{2+}$<\/span>) channels, halting the depolarization-induced exocytosis of excitatory nociceptive neurotransmitters (substance P, calcitonin gene-related peptide [CGRP], and L-glutamate).<\/p>\n<\/li>\n Postsynaptically, it opens G-protein-coupled inwardly rectifying potassium (GIRK) channels. The resulting potassium ion efflux hyperpolarizes the neuronal membrane, preventing action potential propagation along ascending spinothalamic tracts.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Direct Intrinsic Action vs. Active Metabolites:<\/b> Unlike codeine, oxycodone does not function as a prodrug and does not require hepatic bioactivation to exert clinical analgesia<\/b>. The intact parent molecule drives approximately $80\\%$<\/span> of its total central analgesic effect. While CYP2D6 metabolizes a minor fraction into oxymorphone<\/b> (which exhibits a $\\sim 10$<\/span>-fold higher affinity for the $\\mu$<\/span>-receptor than parent oxycodone), circulating oxymorphone concentrations are low, meaning variations in CYP2D6 status do not significantly alter the primary analgesic response.<\/p>\n<\/li>\n Relative Potency and Morphine Equivalence:<\/b> Oxycodone is a Step 3 opioid:<\/p>\n Oral oxycodone exhibits an equianalgesic potency ratio of approximately $1.5:1\\text{ to }2:1$<\/span> relative to oral morphine<\/b>.<\/p>\n<\/li>\n A single OxyDolor 40mg tablet taken every 12 hours delivers analgesic exposure equivalent to $120\\text{ to }160\\text{ mg}$<\/span> of oral morphine sulphate<\/b> over a 24-hour period.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Respiratory and Enteric Depression:<\/b> Agonism within the pontomedullary respiratory centers (the pre-B\u00f6tzinger complex) blunts chemoreceptor sensitivity to arterial carbon dioxide ($\\text{PaCO}_2$<\/span>) and hypoxia, causing dose-dependent bradypnea. In the gastrointestinal tract, stimulation of myenteric $\\mu$<\/span>-receptors inhibits propulsive peristalsis and increases circular sphincter tone, universally causing severe constipation.<\/p>\n<\/li>\n<\/ul>\n OxyDolor 40mg is indicated for patients who are already established on opioid therapy<\/b> and require high-potency Step 3 analgesia under BNF and European Association for Palliative Care (EAPC) guidelines:<\/p>\n Severe Cancer-Related Pain:<\/b><\/p>\n Indicated for the long-term management of severe chronic pain in malignant disease when non-opioid or weak opioid analgesics (Step 2) fail to achieve adequate pain control.<\/p>\n<\/li>\n Dosed strictly on a 12-hourly schedule<\/b> ($40\\text{ mg}$<\/span> twice daily). Breakthrough pain is managed using an immediate-release oral oxycodone formulation (e.g., OxyNorm liquid or capsules), calculated at one-sixth to one-tenth of the total 24-hour baseline dose (e.g., $10\\text{ to }15\\text{ mg}$<\/span> immediate-release PRN for an $80\\text{ mg\/day}$<\/span> total prolonged-release regimen).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe Non-Malignant Chronic Pain (Specialist-Directed):<\/b><\/p>\n Indicated for severe, refractory chronic non-malignant pain (e.g., severe osteoarthritic destruction, advanced neuropathic syndromes, failed back surgery syndrome) only when comprehensive non-opioid strategies have failed.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Tolerance Requirements and Opioid-Naive Warning:<\/b><\/p>\n OxyDolor 40mg is contraindicated in opioid-naive patients.<\/b><\/p>\n<\/li>\n Initiation of a 40mg tablet twice daily is reserved exclusively for patients already tolerant to Step 3 opioids\u2014defined by receiving continuous, stable daily opioid therapy equivalent to at least $60\\text{ to }80\\text{ mg}$<\/span> of oral morphine sulphate, or $30\\text{ to }40\\text{ mg}$<\/span> of oral oxycodone daily, for at least two consecutive weeks.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n NICE Guidance on Chronic Non-Cancer Pain (NG193):<\/b><\/p>\n NICE explicitly advises against initiating high-potency opioids for chronic primary pain due to lack of evidence for long-term functional recovery, high dependence liabilities, and the risk of opioid-induced hyperalgesia (OIH). Prescriptions must be accompanied by defined functional goals, scheduled reviews, and an agreed tapering\/exit strategy.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n In non-medical or illicit contexts, OxyDolor 40mg is abused for euphoric intoxication, sedation, and emotional blunting. Tablets are frequently manipulated (crushed for nasal insufflation or dissolved for intravenous injection) to bypass the diffusion matrix, creating high risks of fatal overdose.<\/p>\n The pharmacokinetic behavior of OxyDolor 40mg depends on maintaining matrix integrity to ensure controlled, 12-hour dissolution:<\/p>\n $N$<\/span>-Demethylation via CYP3A4 (Major Pathway, $\\sim 80\\%$<\/span>):<\/b> Converts oxycodone into noroxycodone<\/b>. Noroxycodone is a weak $\\mu$<\/span>-opioid agonist with poor blood-brain barrier permeability, contributing negligibly to analgesia.<\/p>\n<\/li>\n $O$<\/span>-Demethylation via CYP2D6 (Minor Pathway, $\\sim 10\\%$<\/span>):<\/b> Converts oxycodone into oxymorphone<\/b>, a potent $\\mu$<\/span>-opioid agonist. Although oxymorphone has high receptor affinity, its circulating plasma concentrations are low, meaning that genetic CYP2D6 variations (poor vs. ultra-rapid metabolizers) do not meaningfully alter the overall analgesic response.<\/p>\n<\/li>\n Secondary Glucuronidation:<\/b> Phase II UDP-glucuronosyltransferases conjugate parent drug and oxidized metabolites into polar glucuronide conjugates for renal excretion.<\/p>\n<\/li>\n Renal Clearance Dynamics:<\/b> Less than $10\\%$<\/span> is excreted unchanged in the urine. In patients with severe renal impairment (eGFR $<30\\text{ mL\/min\/1.73 m}^2$<\/span>), total drug exposure ($AUC$<\/span>) increases by $40\\text{ to }60\\%$<\/span>, requiring conservative dose titration and extended dosing intervals.<\/p>\n<\/li>\n<\/ol>\n Therapeutic administration produces potent analgesia and suppression of pain-associated autonomic distress. However, extensive $\\mu$<\/span>-opioid receptor engagement across multiple organ systems produces a characteristic spectrum of adverse effects:<\/p>\n Gastrointestinal Disturbances (Very Common, $\\ge 1\/10$<\/span>):<\/b><\/p>\n Constipation:<\/b> Occurs in up to $80\\%$<\/span> of treated individuals. Opioid receptor binding in the myenteric plexus inhibits propulsive peristalsis and arrests secretomotor fluid transport. Tolerance does not develop; co-prescribing a prophylactic laxative regimen is clinically mandatory.<\/p>\n<\/li>\n Nausea and vomiting: Triggered by direct stimulation of the chemoreceptor trigger zone (CTZ) in the area postrema.<\/p>\n<\/li>\n Xerostomia (dry mouth), dyspepsia, and biliary spasm (constriction of the Sphincter of Oddi).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Central Nervous System and Neuropsychiatric Toxicity (Common, $1\/100$<\/span> to $<1\/10$<\/span>):<\/b><\/p>\n Somnolence, daytime sedation, dizziness, headache, and cognitive clouding.<\/p>\n<\/li>\n Euphoria or paradoxical restlessness, dysphoria, and confusion (more frequent in elderly patients).<\/p>\n<\/li>\n Muscle fasciculations, myoclonus, and hyperalgesia (associated with high-dose accumulation).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Cutaneous Reactions:<\/b><\/p>\n Pruritus, flushing, and diaphoresis. Oxycodone induces significantly less mast-cell degranulation than morphine, but pruritus remains common due to central $\\mu$<\/span>-receptor mechanisms.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe, Emergent and Life-Threatening Hazards (Overdose & Dependence):<\/b><\/p>\n Catastrophic Central Respiratory Depression:<\/b> The primary cause of fatal poisoning. Suppression of the medullary pre-B\u00f6tzinger complex produces severe bradypnea ($<8\\text{ breaths\/min}$<\/span>), progressive cyanosis, stupor advancing to coma, hypercapnic acidosis, and fatal cardiac arrest.<\/p>\n<\/li>\n Dose-Dumping Toxicity:<\/b> If an OxyDolor 40mg tablet is chewed, crushed, or dissolved, the entire $40\\text{ mg}$<\/span> payload is released immediately ($C_{max}$<\/span> occurs within 30 to 45 minutes rather than 6 to 8 hours), predisposing opioid-naive or partially tolerant individuals to acute respiratory failure.<\/p>\n<\/li>\n Synergistic Depressant Collapse:<\/b> Co-ingestion with alcohol, benzodiazepines, or gabapentinoids (pregabalin, gabapentin)<\/b> dramatically amplifies medullary depression, causing rapid loss of consciousness, airway compromise, and fatal asphyxiation.<\/p>\n<\/li>\n Physical Dependence and Acute Opioid Withdrawal:<\/b> Continuous use beyond 2 to 4 weeks drives neuroadaptation. Abrupt discontinuation precipitates a severe withdrawal syndrome: autonomic hyperactivity (tachycardia, hypertension, diaphoresis), gastrointestinal cramping, diarrhea, piloerection (“cold turkey”), pupil dilation (mydriasis), myalgias, and severe insomnia.<\/p>\n<\/li>\n Counterfeit Nitazene Poisoning:<\/b> Black-market tablets sold as “Oxy 40” frequently contain synthetic nitazene opioids<\/b> (e.g., protonitazene, metonitazene), which exhibit potencies tens to hundreds of times higher than morphine, causing rapid, severe respiratory arrest that requires massive, escalated doses of naloxone.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Prescribing, titrating, and monitoring OxyDolor 40mg mandates strict adherence to safety exclusions, metabolic drug-interaction screening, and Controlled Drugs governance:<\/p>\n Contraindications:<\/b><\/p>\n Opioid-Naive Patients:<\/b> Absolute Contraindication.<\/b> Initiating a 40mg dose in non-tolerant individuals carries an extreme risk of fatal respiratory depression.<\/p>\n<\/li>\n Severe Respiratory Depression:<\/b> Absolute contraindication in acute respiratory failure, severe chronic obstructive pulmonary disease (COPD), respiratory arrest, or acute severe asthma.<\/p>\n<\/li>\n Paralytic Ileus or Obstructive Bowel Disease:<\/b> Absolute contraindication due to the risk of precipitating toxic megacolon or bowel perforation.<\/p>\n<\/li>\n Raised Intracranial Pressure (ICP) and Severe Head Injury:<\/b> Opioid-induced $\\text{CO}_2$<\/span> retention promotes cerebral vasodilation, dangerously spiking intracranial pressure.<\/p>\n<\/li>\n Severe Hepatic Cirrhosis (Child-Pugh Class C):<\/b> Clearance of parent drug is severely blunted, leading to massive, uncontrolled drug accumulation.<\/p>\n<\/li>\n Concurrent Monoamine Oxidase Inhibitors (MAOIs):<\/b> Absolute contraindication during or within 14 days of MAOI therapy.<\/p>\n<\/li>\n Pregnancy and Breastfeeding:<\/b> Avoided during pregnancy unless essential (risks neonatal respiratory depression and neonatal opioid withdrawal syndrome [NOWS]); contraindicated in nursing mothers (oxycodone concentrates in breast milk, causing fatal infant sedation).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Drug Interactions:<\/b><\/p>\n Potent Cytochrome P450 3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Ritonavir, Grapefruit Juice):<\/i> High-Level Hazard.<\/b> Inhibiting CYP3A4 shuts down the primary clearance pathway of oxycodone, increasing plasma $AUC$<\/span> by $100\\text{ to }200\\%$<\/span><\/b> and doubling its elimination half-life, transforming a standard maintenance dose into a dangerous overdose.<\/p>\n<\/li>\n\n
\n
2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
\n
\n
3. Approved UK and European Clinical Indications and Therapeutic Scope<\/h2>\n
\n
\n
\n
\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n\n
\n Pharmacokinetic Parameter<\/strong><\/td>\n Value \/ Metric<\/strong><\/td>\n Clinical Interpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Oral Bioavailability<\/b><\/span><\/td>\n $60\\text{ to }87\\%$<\/span><\/b><\/span><\/td>\n High and reliable compared to oral morphine ($20\\text{\u2013}40\\%$<\/span>).<\/span><\/td>\n<\/tr>\n \n Release Pattern \/ $T_{max}$<\/span><\/b><\/span><\/td>\n Biphasic: Initial peak at $1\\text{ to }3\\text{ hours}$<\/span><\/b>, broad second peak at $6\\text{ to }8\\text{ hours}$<\/span><\/b><\/span><\/td>\n Sustains constant therapeutic plasma concentrations over 12 hours.<\/span><\/td>\n<\/tr>\n \n Volume of Distribution ($V_{ss}$<\/span>)<\/b><\/span><\/td>\n $2.6\\text{ to }3.2\\text{ L\/kg}$<\/span><\/b><\/span><\/td>\n Extensive extravascular and central nervous system tissue distribution.<\/span><\/td>\n<\/tr>\n \n Plasma Protein Binding<\/b><\/span><\/td>\n $\\sim 45\\%$<\/span> (Moderate)<\/span><\/td>\n Bound primarily to human serum albumin; low displacement interaction risk.<\/span><\/td>\n<\/tr>\n \n Primary Hepatic Enzymes<\/b><\/span><\/td>\n CYP3A4<\/b> ($\\sim 80\\%$<\/span>), CYP2D6<\/b> ($\\sim 10\\%$<\/span>)<\/span><\/td>\n High susceptibility to systemic CYP3A4 inhibitors and inducers.<\/span><\/td>\n<\/tr>\n \n Active Metabolites<\/b><\/span><\/td>\n Oxymorphone<\/b> (potent, low concentration), Noroxycodone (weak)<\/span><\/td>\n Parent drug drives the overwhelming majority of clinical efficacy.<\/span><\/td>\n<\/tr>\n \n Elimination Route<\/b><\/span><\/td>\n Renal ($80\\%$<\/span>, unconjugated drug and metabolites)<\/span><\/td>\n Elimination is prolonged in moderate-to-severe renal failure.<\/span><\/td>\n<\/tr>\n \n Elimination Half-Life ($t_{1\/2}$<\/span>)<\/b><\/span><\/td>\n Apparent $t_{1\/2} \\approx \\mathbf{4.5\\text{ to }6.5\\text{ hours}}$<\/span><\/span><\/td>\n Prolonged by ongoing release from the polymer matrix (flip-flop kinetics).<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Biotransformation Cascades<\/h3>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
\n
\n
\n